Miguel Chuquilin, MD
Vascular Neurology · Tallahassee, FLNPI 1982633251
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,487 of the $30,446 with a category attached, or 80.4%. 19 manufacturers reported payments, led by AstraZeneca at 36.1% of the total. Reporting peaked in 2024 at $23,026 and has fallen 83.1% since, to $3,884 in 2025.
Across 71 payments — averaging $428.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Sarepta Therapeutics, Inc.$10K
- Amgen$3K
- Argenx US, Inc.$2K
- Johnson & Johnson$2K
- UCB, Inc.$1K
- plus $1K from 13 others
What the payments were for
- Consulting fees$24,48780%
- Travel & lodging$3,45611%
- Food & beverage$2,5038%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $10,991 |
| Sarepta Therapeutics, Inc. | 11 | $10,232 |
| Amgen(2 entities) | 4 | $2,633 |
| Argenx US, Inc. | 6 | $2,301 |
| Johnson & Johnson | 2 | $1,798 |
| UCB, Inc. | 2 | $1,435 |
| TG Therapeutics, Inc. | 7 | $310 |
| Medtronic | 1 | $166 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $90 |
| SK Life Science, Inc. | 2 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Neurelis, Inc. | 2 | $47 |
| Pfizer | 2 | $43 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Novartis | 1 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,446 in reported general payments places this provider in the 85th percentile of 40 vascular neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $174,081 |
| AustedoDeutetrabenazine | 11 | $96,889 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $61,004 |
| BriviactBrivaracetam | 28 | $39,404 |
| Rivastigmine | 65 | $15,222 |
| Lamotrigine ErLamotrigine | 13 | $10,850 |
| Lacosamide | 45 | $8,446 |
| Memantine Hcl | 287 | $7,997 |
| Donepezil Hcl | 319 | $3,097 |
| Doxepin Hcl | 11 | $2,561 |
| Levetiracetam | 68 | $2,400 |
| Memantine Hcl ErMemantine Hcl | 13 | $2,030 |
| Carbamazepine ErCarbamazepine | 16 | $1,886 |
| Galantamine Hbr | 13 | $1,641 |
| Duloxetine Hcl | 45 | $1,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $90 | $174,08111 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $24 | $96,88911 claims |
| UCB, Inc.Briviact | $1,435 | $39,40428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 40 vascular neurology providers in Florida.
Other vascular neurology in Tallahassee
- Maxim MokinTampa$137K
- Robert MannelJacksonville Beach$92K
- Alexander SenetarSarasota$42K
- Amin AghaebrahimJacksonville$36K
- Richard CallisonFort Pierce$28K
- Farah FourcandVero Beach$11K
- John CasselTampa$10K
- William BurginTampa$9K
- Mehdi BouslamaFort Lauderdale$8K
- Ritesh KaushalHialeah$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.